论文部分内容阅读
目的比较伊立替康加顺铂(CPT11+DDP)及依托泊苷加顺铂(VP16+DDP)两种方案一线治疗小细胞肺癌的临床疗效、不良反应。方法初治小细胞肺癌患者67例,IP组34例患者,应用DDP 40mg/m2静脉滴注,d1～d3,CPT～1160mg/m2静脉滴注,d1、d8、d15。EP组33例患者,应用方案DDP 40mg/m2静脉滴注,VP-16100mg/m2静脉滴注,d1～d5,两种方案均为28d为一个周期,连用4～6个周期。两个周期后评价疗效及不良反应。结果 IP组有效率58.8%,EP组有效率39.4%,两组比较差异有统计学意义(P<0.05);IP组无进展生存期4.1个月,EP组无进展生存期2.9个月,两组比较差异无统计学意义(P>0.05);两组不良反应发生率比较差异均无统计学意义,P>0.05。结论与依托泊泔联合顺铂方案相比,伊立替康联合顺铂方案疗效相似,不良反应相近,且无进展生存期延长,是小细胞肺癌一线治疗的安全有效方案。
Objective To compare the clinical efficacy and side effects of first-line treatment of small cell lung cancer with irinotecan plus cisplatin (CPT11 + DDP) and etoposide plus cisplatin (VP16 + DDP). Methods 67 patients with newly diagnosed small cell lung cancer and 34 patients with IP were treated with intravenous drip of DDP 40mg / m2, d1 ~ d3, CPT ~ 1160mg / m2, d1, d8 and d15. EP group 33 patients, the application of DDP 40mg / m2 intravenous infusion, VP-16100mg / m2 intravenous infusion, d1 ~ d5, both programs are 28d for a cycle, once every 4 to 6 cycles. After two cycles evaluation of efficacy and adverse reactions. Results The effective rate of IP group was 58.8% and that of EP group was 39.4%, there was significant difference between the two groups (P <0.05). The progression-free survival time in IP group was 4.1 months, and the progression-free survival time in EP group was 2.9 months There was no significant difference between the two groups (P> 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion Compared with etoposide combined with cisplatin, irinotecan combined with cisplatin has similar curative effect, similar side effects and no progression-free survival. It is safe and effective for first-line treatment of small cell lung cancer.